RxDoctor Payments Data

Walter Longo, MD

Hematology & Oncology · Milwaukee, WINPI 1629044649

Payments from drug & device makers

$66,821in general payments, 2019–2025

Across 15 payments — averaging $4454.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma Global Development$54K
  • National Marrow Donor Program$7K
  • Bristol Myers Squibb$5K
  • CSL Behring$798
  • Janssen Scientific Affairs, LLC$150
  • Incyte Corporation$136

What the payments were for

  • Consulting fees$1503%
  • Speaking & faculty fees$4,87591%
  • Travel & lodging$791%
  • Food & beverage$2615%

General payments by program year

19
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$66,821 in reported general payments places this provider in the 70th percentile of 248 hematology & oncology providers in Wisconsin.

See all hematology & oncology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$46,117
Medicare patients
144
Services billed
536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate27$414,027
RezurockBelumosudil Mesylate13$403,256
BrukinsaZanubrutinib17$166,276
CalquenceAcalabrutinib Maleate11$163,510
EliquisApixaban27$15,746
Acyclovir63$1,478
Fluconazole32$1,157
Oxycodone Hcl26$765
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim59$531
Armour ThyroidThyroid,pork15$480
Morphine Sulfate ErMorphine Sulfate13$385
Dexamethasone15$285
Lorazepam25$161
Azithromycin12$160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$136$414,02727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 248 hematology & oncology providers in Wisconsin.

Other hematology & oncology in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →